Je was op zoek naar: filgrastimom (Sloveens - Engels)

prekinite zdravljenja s filgrastimom
discontinue filgrastim

vzročna povezava s filgrastimom ni bila ugotovljena.
the causal association with filgrastim has not been established.

neposredna posledica zdravljenja s filgrastimom je splenomegalija.
splenomegaly is a direct effect of treatment with filgrastim.

zvečanje vranice je neposreden učinek zdravljenja s filgrastimom.
splenic enlargement is a direct effect of treatment with filgrastim.

(5 µg) / kg/ dan prekinite zdravljenja s filgrastimom
then, if anc remains > 1.0 x 10 / l for 3 more consecutive days

prejemniki alogenskih matičnih celic iz periferne krvi izplavljenih s filgrastimom.
recipients of allogeneic pbpcs mobilised with filgrastim

pri rakavih bolnikih, zdravljenih s filgrastimom, so poročali o psevdoprotinu.
pseudogout has been reported in patients with cancer treated with filgrastim.

pri bolnikih z rakom, zdravljenih s filgrastimom, so poročali o hondrokalcinozi.
pseudogout has been reported in patients with cancer treated with filgrastim.

psevdoputika je bila zaznana pri rakavih bolnikih,ki so bili zdravljeni s filgrastimom.
pseudogout has been reported in patients with cancer treated with filgrastim.

v tem primeru je treba prekiniti zdravljenje s filgrastimom in poskrbeti za ustrezno zdravljenje.
filgrastim should be discontinued and appropriate treatment given in these cases.

zaradi mielosupresivne kemoterapije zdravljenje samo s filgrastimom ne zadostuje za preprečevanje trombocitopenije in anemije.
treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy.

glede na objavljene podatke so med zdravljenjem s filgrastimom opazili naslednje neželene učinke in pogostnosti.
the following undesirable effects and their frequencies have been observed under treatment with filgrastim based on published information.

zdravljenje s filgrastimom samim ne prepreči trombocitopenije in anemije, ki se pojavita zaradi mielosupresivne kemoterapije.
treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy.

pri manj kot 10 % bolnikov sta se kmalu po začetku terapije s filgrastimom pojavila glavobol in diareja.
headache and diarrhoea have been reported shortly after starting filgrastim therapy, typically in less than 10 % of patients.

prezgodnja prekinitev zdravljenja s filgrastimom, preden število nevtrofilcev pade na pričakovano najnižjo raven, ni priporočljiva.
premature discontinuation of filgrastim therapy prior to the time of the expected neutrophil nadir is not recommended.

povečanje, zmerjeno z radiografijo, se je pojavilo v zgodnji fazi zdravljenja s filgrastimom, nato pa se je umirilo.
8 radiographically, occurred early during filgrastim therapy and tended to plateau.

ni nobenih dokazov za to, da bi pri bolnikih, okuženih s hiv, zdravljenje s filgrastimom povzročilo povečanje replikacije hiv.
there is no evidence that patients with hiv infection treated with filgrastim show an increase in hiv replication.

absolutno število nevtrofilcev (anc) je treba skrbno spremljati, zlasti v obdobju prvih nekaj tednov zdravljenja s filgrastimom.
absolute neutrophil count (anc) should be monitored closely, especially during the first few weeks of filgrastim therapy.